Key Gene Plays Crucial Role in Malignant Transformation

Publication
Article
OncologyONCOLOGY Vol 11 No 2
Volume 11
Issue 2

A major gene essential for controlling the synthesis of hereditary material and cell proliferation is also critically involved in determining the extent of malignant growth of cancer cells, reports a study published in a recent issue of the Proceedings of

A major gene essential for controlling the synthesis of hereditary materialand cell proliferation is also critically involved in determining the extentof malignant growth of cancer cells, reports a study published in a recentissue of the Proceedings of the National Academy of Sciences.

According to the new study, early cancer cells interacting with theR2 gene became highly malignant, producing tumor-like colonies and metastatictumor growth.

The study, performed at the Manitoba Institute of Cell Biology (MICB)at the University of Manitoba in Winnipeg, Canada, confirms the R2 geneas a key determinant of malignancy, say researchers, and suggests the greattherapeutic potential of two new cancer-fighting treatments that specificallytarget this gene.

The developer of these treatments, Dr. Jim A. Wright, chief researcherin the MICB study, said he believed it constituted "a vital step forward"in the understanding of the specific genetic factors responsible for producingaggressive malignant tumor growth. "We believe our discoveries willnot only help us in improving our understanding of cancer progression,"he said, "but also in refining chemotherapy and gene therapy treatmentsthat directly modify gene expression and interfere with disease relatedmolecular pathways."

In cooperation with Dr. A. Young of GeneSense Technologies, a drug researchcompany in Winnipeg, Dr. Wright has developed two compounds designed toact against the R2 gene, minimizing its ability to promote tumor cell growth.These therapies, he said, are designed to keep abnormal cells at a precancerousstage or in a localized, slow-growing tumor where they can be more effectivelytreated.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.